Healthcare/Biotech
|
Updated on 06 Nov 2025, 07:50 am
Reviewed By
Simar Singh | Whalesbook News Team
▶
Indoco Remedies Limited announced its second-quarter financial results, showing an improvement in its net loss, which narrowed to ₹8 crore from ₹9.6 crore in the corresponding quarter of the previous fiscal year. The company's revenue demonstrated healthy growth, increasing by 12% to ₹485 crore from ₹433 crore year-on-year. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) also saw a rise of 6.6%, reaching ₹43.4 crore, up from ₹41 crore in the prior year. However, the company's EBITDA margins experienced a marginal contraction, moving from 9.4% to 9.0% compared to the year-ago period.
In contrast, the first quarter of the financial year 2026 presented a more challenging picture, with Indoco Remedies reporting a net loss of ₹35.6 crore and a significant decline in EBITDA by 62.8%. Revenue for the first quarter grew by a modest 1.5%.
Following the Q2 results, shares of Indoco Remedies gained on Thursday, November 6. The stock was trading up 1.5% at approximately ₹275 around 11:55 am. Over the last six months, the stock has appreciated by 14.4%, although it has seen a decline of nearly 18% year-to-date.
Impact This positive earnings report is likely to boost investor confidence, potentially leading to sustained stock price appreciation and improved market sentiment for Indoco Remedies Limited. Rating: 6/10
Difficult Terms Explained: EBITDA: Earnings Before Interest, Taxes, Depreciation, and Amortization. This metric indicates a company's operating performance by excluding interest expenses, taxes, and non-cash charges like depreciation and amortization. EBITDA Margin: This is calculated by dividing EBITDA by total revenue. It measures the profitability of a company's core operations as a percentage of its sales, indicating how efficiently the company is generating earnings from its revenue. Net Loss: Occurs when a company's total expenses exceed its total revenue over a specific period. Revenue: The total income generated by the sale of goods or services related to the company's primary operations.
Healthcare/Biotech
Medi Assist Healthcare Profit Drops 61.6% Amidst Acquisition and Tech Investments
Healthcare/Biotech
Sun Pharma's US Innovative Drug Sales Surpass Generics for First Time
Healthcare/Biotech
Indoco Remedies Posts Improved Q2 Earnings, Stock Sees Gains
Healthcare/Biotech
Zydus Lifesciences' Beta-Thalassemia Drug Desidustat Receives USFDA Orphan Drug Designation
Healthcare/Biotech
Abbott India Reports 16% Profit Jump on Strong Revenue and Margins
Healthcare/Biotech
Zydus Lifesciences Reports 39% Profit Growth in Q2 FY26, Plans ₹5,000 Crore Fundraising
Energy
Vedanta Secures 500 MW Power Supply Pact with Tamil Nadu for Five Years
Banking/Finance
Cholamandalam Investment Reports 20% Profit Growth in Q2FY26 Amid Rising NPAs
Economy
India Services Sector Growth Slows to 5-Month Low in October
Consumer Products
India's Consumer Sector Faces Sweeping Leadership Overhaul
Economy
India’s Richest Donate Record Rs 10,380 Crore in 2025, Education Top Priority
Tech
Pine Labs IPO Set to Open November 7, 2025, Targeting Rs 3,899 Crore
Transportation
Manipur Gets Boost: New Flights and Fare Cap on Key Routes Amidst Connectivity Woes
Agriculture
UN Deputy Secretary-General Urges Alignment of Global Food Systems with Climate Action at COP30